FDA Approval Opens New Possibilities for Hepatitis B Patients

KARACHI: The US Food and Drug Administration (FDA) has approved British pharmaceutical company GSK’s Hibsago, a new treatment for chronic hepatitis B that could help some patients achieve sustained control of the virus after stopping antiviral therapy.

The medicine, known by its generic name bepirovirsen, is the first FDA-approved antisense oligonucleotide for chronic hepatitis B. It works by reducing the production of viral RNA and proteins associated with the hepatitis B virus (HBV). This lowers levels of hepatitis B surface antigen (HBsAg) in the blood and may also help stimulate the immune system to achieve a lasting response.

The approval marks a potential advance in the treatment of a disease that remains a major global public health challenge. Although existing antiviral medicines can suppress the virus, most patients require long-term treatment, and sustained viral clearance remains difficult to achieve.

Clinical Trials Show Promise for Sustained Viral Control

Clinical trial results indicate that nearly one in five patients treated with bepirovirsen achieved undetectable levels of hepatitis B virus and remained off antiviral treatment for at least six months.

The findings come from the B-Well 1 and B-Well 2 trials, global, multicentre studies conducted across 29 countries. Both trials used a randomised, double-blind and placebo-controlled design to assess the treatment’s effectiveness.

The results suggest that bepirovirsen could offer a new approach for patients who hope to maintain viral control without continuing standard antiviral therapy. However, treatment outcomes can vary, and the potential benefits need to be considered alongside the medicine’s approved prescribing information and medical guidance.

Hepatitis B Remains a Major Global Health Concern

Hepatitis B is a viral infection that can cause both acute and chronic liver disease. Chronic infection develops when the immune system cannot clear the virus, allowing it to persist in the body and potentially cause serious complications over time.

According to the figures provided in the announcement, more than 240 million people worldwide live with chronic hepatitis B. The disease causes approximately 1.1 million deaths each year and is the leading cause of liver cancer cases globally.

Current standard treatments primarily aim to suppress viral replication and reduce the risk of liver damage. However, only around 1% to 4% of patients achieve sustained viral clearance, often described by doctors as a functional cure.

Against this backdrop, treatments that can improve the likelihood of a durable response could represent an important development in long-term hepatitis B management.

Hibsago’s Regulatory Status Beyond the United States

Hibsago (bepirovirsen) has also received approval in Japan, according to the announcement. The medicine remains under regulatory review in China and Europe, where authorities are assessing its potential use.

The US approval adds to the treatment’s international regulatory progress and could expand access for eligible patients, subject to local availability and prescribing requirements.

While the clinical findings offer encouragement, continued medical supervision remains important for people living with chronic hepatitis B. Patients should consult qualified healthcare professionals before making any changes to their existing treatment.